Type I IFNs enhance the terminal differentiation of dendritic cells

Journal of Immunology

Volumn 161, Issue 4, 1998, Pages 1947-1953

  Luft, Thomas ^a,e   Pang, Ken C ^a   Thomas, Elisabeth ^a   Hertzog, Paul ^b   Hart, Derek N J ^c   Trapani, Joseph ^d   Cebon, Jonathan ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d AUSTIN RESEARCH INSTITUTE   (Australia)

^e OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD1 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LANGERHANS CELL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE I; INTERFERON-ALPHA; SKIN; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032529213     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
2. Jaeger, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilsemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66:162.
3. Marchand, M., P. Weynants, E. Rankin, F. Arienti, F. Belli, G. Parmiani, N. Cascinelli, A. Bourlond, R. Vanwijck, Y. Humblet, and et al. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int. J. Cancer 63:883.
4. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. DeLeo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med 1:1297.
5. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
6. Van Voorhis, W. C., L. S. Hair, R. M. Steinman, and G. Kaplan. 1982. Human dendritic cells: enrichment and characterization from peripheral blood. J. Exp. Med. 155:1172.
7. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109.
8. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83.
9. Caux, C., C. Dezutter Dambuyant, D. Schmitt, and J. Banchereau. 1992. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360:258.
10. + progenitor cells. Exp. Hematol. 26:489.
11. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:389.
12. Stossel, H., F. Koch, E. Kampgen, P. Stoger, A. Lenz, C. Heufler, N. Romani, and G. Schuler. 1990. Disappearance of certain acidic organelles (endosomes and Langerhans cell granules) accompanies loss of antigen processing capacity upon culture of epidermal Langerhans cells. J. Exp. Med. 172:1471.
13. Romani, N., S. Koide, M. Crowley, M. Witmer Pack, A. M. Livingstone, C. G. Fathman, K. Inaba, and R. M. Steinman. 1989. Presentation of exogenous protein antigens by dendritic cells to T cell clones: intact protein is presented best by immature, epidermal Langerhans cells. J. Exp. Med. 169:1169.
14. Kampgen, E., N. Koch, F. Koch, P. Stoger, C. Heufler, G. Schuler, and N. Romani. 1991. Class II major histocompatibility complex molecules of murine dendritic cells: synthesis, sialylation of invariant chain, and antigen processing capacity are down-regulated upon culture. Proc. Natl. Acad. Sci. USA 88:3014.
15. Streilein, J. W., and S. F. Grammer. 1989. In vitro evidence that Langerhans cells can adopt two functionally distinct forms capable of antigen presentation to T lymphocytes. J. Immunol. 143:3925.
16. Dai, R., and J. W. Streilein. 1993. In vitro culture allows splenic dendritic cells to reach their full potential for T-cell activation. Reg. Immunol. 5:269.
17. O'Doherty, U., R. M. Steinman, M. Peng, P. U. Cameron, S. Gezelter, I. Kopeloff, W. J. Swiggard, M. Pope, and N. Bhardwaj. 1993. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J. Exp. Med. 178:1067.
18. Teunissen, M. B., J. Wormmeester, S. R. Krieg, P. J. Peters, I. M. Vogels, M. L. Kapsenberg, and J. D. Bos. 1990. Human epidermal Langerhans cells undergo profound morphologic and phenotypical changes during in vitro culture. J. Invest. Dermatol. 94:166.
19. Larsen, C. P., S. C. Ritchie, R. Hendrix, P. S. Linsley, K. S. Hathcock, R. J. Hodes, R. P. Lowry, and T. C. Pearson. 1994. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152:5208.
20. Yokozeki, H., I. Katayama, O. Ohki, T. Matsunaga, K. Watanabe, T. Satoh, M. Azuma, K. Okumura, and K. Nishioka. 1996. Functional CD86 (B7-2/B70) on cultured human Langerhans cells. J. Invest. Dermatol. 106:147.
21. Macatonia, S. E., A. J. Edwards, and S. C. Knight. 1986. Dendritic cells and the initiation of contact sensitivity to fluorescein isothiocyanate. Immunology 59:509.
22. Knight, S. C., J. Krejci, M. Malkovsky, V. Colizzi, A. Gautam, and G. L. Asherson. 1985. The role of dendritic cells in the initiation of immune responses to contact sensitizers. I. In vivo exposure to antigen. Cell. Immunol. 94:427.
23. Cumberbatch, M., and I. Kimber. 1992. Dermal tumour necrosis factor-α induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration. Immunology 75:257.
24. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263.
25. Hock, B. D., G. C. Starling, P. B. Daniel, and D. N. Hart. 1994. Characterization of CMRF-44, a novel mAb to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 83: 573.
26. Hamilton, J. A., G. A. Whitty, I. Kola, and P. J. Hertzog. 1996. Endogenous IFN-αβ suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-α. J. Immunol. 156:2553.
27. Frelinger, J. G., L. Hood, S. Hill, and J. A. Frelinger. 1979. Mouse epidermal Ia molecules have a bone marrow origin. Nature 282:321.
28. Katz, S. I., K. Tamaki, and D. H. Sachs. 1979. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 282:324.
29. Silberberg-Sinakin, I., G. J. Thorbecke, R. L. Baer, S. A. Rosenthal, and V. Berezowsky. 1976. Antigen-bearing langerhans cells in skin, dermal lymphatics and in lymph nodes. Cell. Immunol. 25:137.
30. Williams, L. A., W. Egner, and D. N. Hart. 1994. Isolation and function of human dendritic cells. Int. Rev. Cytol. 153:41.
31. Johnson, D. R., and J. S. Pober. 1994. HLA class I heavy-chain gene promoter elements mediating synergy between tumor necrosis factor and interferons. Mol. Cell. Biol. 14:1322.
32. Verhasselt, V., C. Buelens, F. Willems, D. De Groote, N. Haeffner-Cavaillon, and M. Goldman. 1997. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J. Immunol. 158:2919.
33. Hertzog, P. J., A. Wright, G. Harris, A. W. Linnane, and I. R. Mackay. 1991. Intermittent interferonemia and interferon responses in multiple sclerosis. Clin. Immunol. Immunopathol. 58:18.
34. van den Broek, M. F., U. Muller, S. Huang, M. Aguet, and R. M. Zinkernagel. 1995. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69:4792.
35. Hwang, S. Y., P. J. Hertzog, K. A. Holland, S. H. Sumarsono, M. J. Tymms, J. A. Hamilton, G. Whitty, I. Bertoncello, and I. Kola. 1995. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. [Published erratum appears in 1996 Proc. Natl. Acad. Sci. USA 93:4519.] Proc. Natl. Acad. Sci. USA 92:11284.
36. Demeure, C. E., C. Y. Wu, U. Shu, P. V. Schneider, C. Heusser, H. Yssel, and G. Delespesse. 1994. In vitro maturation of human neonatal CD4 T lymphocytes. II. Cytokines present at priming modulate the development of lymphokine production. J. Immunol. 152:4775.
37. Belardelli, F. 1995. Role of interferons and other cytokines in the regulation of the immune response. APMIS 103:161.
38. + T cells. J. Exp. Med. 178:1655.
39. Ronnblom, L. E., G. V. Aim, and K. Oberg. 1991. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-α treatment. Acta Oncol. 30:537.
40. Gisslinger, H., B. Gilly, W. Woloszczuk, W. R. Mayr, L. Havelec, W. Linkesch, and M. Weissel. 1992. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-α. Clin. Exp. Immunol. 90:363.
41. Preziati, D., L. La Rosa, G. Covini, R. Marcelli, S. Rescalli, L. Persani, E. Del Ninno, P. L. Meroni, M. Colombo, and P. Beck Peccoz. 1995. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon α-2a. Eur. J. Endocrinol. 132:587.
42. Tsavaris, N., C. Baxevanis, P. Kosmidis, and M. Papamichael. 1996. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b. Cancer Immunol. Immunother. 43:94.
43. Kirkwood, J. M., D. Wazer, and M. Rosenstein. 1997. Interferon adjuvant therapy of melanoma. Cancer 79:1843.
44. Real, F. X., H. F. Oettgen, and S. E. Krown. 1986. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J. Clin. Oncol. 4:551.
45. Foon, K. 1997. Hairy cell leukemia, chronic myelogenous leukemia and myeloproliferative disorders. In Biologic Therapy of Cancer, 2nd Ed. V. De Vita, S. Hellman, and S. Rosenberg, eds. J. B. Lippincott Co., Philadelphia, p. 365.
46. Sama, G., R. Figlin, and J. de Kernion. 1987. Interferon in renal cell carcinoma: the UCLA experience. Cancer 59:610.
47. Kaido, T., M. T. Bandu, C. Maury, M. Ferrantini, F. Belardelli, and I. Gresser. 1995. IFN-α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int. J. Cancer 60:221.